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ABSTRACT
Background The RATPAC trial showed that using
a point-of-care panel of CK-MB(mass), myoglobin and
troponin at baseline and 90 min increased the proportion
of patients successfully discharged home, leading to
reduced median length of initial hospital stay. However,
it did not change mean hospital stay and may have
increased mean costs per patient. The aim of this study
was to explore variation in outcome and costs between
participating hospitals.
Methods RATPAC was a pragmatic multicentre
randomised controlled trial (N¼2243) and economic
analysis comparing diagnostic assessment using the
panel to standard care for patients with acute chest pain
due to suspected myocardial infarction at six hospitals.
The difference in the proportion of patients successfully
discharged (primary outcome) and mean costs per
patient between the participating hospitals was
compared.
Results Point-of-care assessment led to a higher
proportion of successful discharges in four hospitals,
a lower proportion in one and was equivocal in another.
The OR (95% CI) for the primary outcome varied from
0.12 (0.01 to 1.03) to 11.07 (6.23 to 19.66) with
significant heterogeneity between the centres
(p<0.001). The mean cost per patient for the
intervention group ranged from being £214.49 less than
the control group (132.56 to 657.10) to £646.57 more
expensive (73.12 to 1612.71), with weak evidence of
heterogeneity between the centres (p¼0.0803).
Conclusion The effect of point-of-care panel
assessment on successful discharge and costs per
patient varied markedly between hospitals and may
depend on local protocols, staff practices and available
facilities.
INTRODUCTION
The RATPAC (Randomised Assessment of Treat-
ment using Panel Assay of Cardiac markers) trial
was a pragmatic unblinded randomised controlled
trial comparing point-of-care panel assessment
with a combination of creatine kinase MB enzyme
(CK-MB), myoglobin and cardiac troponin I (cTnI)
at baseline and 90 min, to standard care for patients
with chest pain in whom myocardial infarction
needed to be excluded. It showed that point-of-care
panel assessment resulted in more patients being
successfully discharged after emergency depart-
ment assessment, reduced median length of
hospital stay but not mean length of stay, and
increased use of coronary care.1 An economic
analysis showed that the point-of-care panel
assessment did not save health and social care costs,
may have increased costs and was unlikely to be
considered cost-effective.2
The effects and cost-effectiveness of diagnostic
technologies depend on the setting in which they
are used.3 Factors such as the available facilities
(clinical decision units or observation areas), the
decision-making protocol in use, existing guidelines
and standards, and the attitudes of staff to new
technologies may determine whether diagnostic
tests influence practice in a particular setting. In
particular, when the RATPAC trial was undertaken,
the UK National Health Service was subject
to a national standard requiring 98% of patients
to be admitted or discharged from the emergency
department by 4 h after arrival. The approach
taken by hospitals to achieving the target could
have a significant influence on the impact of the
point-of-care panel.
RATPAC was a multicentre trial involving six
diverse hospitals that each contributed substan-
tially towards patient recruitment. This provided
an opportunity to explore variation between sites
in terms of the facilities available to manage acute
chest pain, the standard care protocols in existence
and the outcomes of the trial. The aim of this study
was to compare the outcomes of the RATPAC trial
in the different settings and determine whether
there was significant variation.
METHODS
The methods of the RATPAC trial1 and economic
evaluation2 are described fully elsewhere but are
briefly outlined below. The trial took place in six
hospitals, as described in table 1. The hospitals
varied in size and facilities, with three having access
to a Clinical Decision Unit.
Adults (age >25 years) were eligible for recruit-
ment if they had acute chest pain due to possible
myocardial infarction (ie, no diagnostic ECG
changes or alternative pathology) within the
previous 12 h and could be discharged home if
diagnostic assessment for myocardial infarction
was negative. Informed consent was sought from
all participants, who were then randomised to
point-of-care panel assessment or standard care
using a web-based randomisation system.
Patients randomised to point-of-care panel
assessment received diagnostic testing with CK-MB
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(as a mass assay), myoglobin and cTnI at baseline and 90 min
using the Seimens Stratus CS analyser. The analytical charac-
teristics of the assays were as follows: cTnI detection limit
0.03 mg/l, analytical range 0.03e50 mg/l, interassay CV 4.0e8.2%
(0.067e0.344 mg/l). The 99th centile of the assay is 0.07 mg/l.
Myoglobin: detection limit 1 mg/l; analytical range 1e900 mg/l;
interassay CV 1.9e12.7% (56e308 mg/l); 95% reference interval,
males 21e98 mg/l, females 19e56 mg/l, combined 20e82 mg/l.
CK-MB: detection limit of 0.3 mg/l; analytical range 0.3e150 mg/l;
interassay CV 0.15e1.27% (3.7e39.3 mg/l); 95% reference
interval 0.6e3.5 mg/l. Hospital admission or discharge was ulti-
mately at the discretion of the physician, but guidelines
provided for the trial recommended admission if there was
a troponin rise above 0.03 mg/l (amended during the trial to
above 0.07 mg/l or a rise from <0.03 mg/l to $0.03 mg/l),
a myoglobin rise of >25% from baseline, a CK-MB elevation
above 5 mg/l at both time points or a CK-MB gradient >1.6 mg/l.
The troponin threshold was amended as emerging experience
with the assay suggested that the initial choice of threshold was
too conservative and resulted in low initial ‘positive’ results that
were not subsequently shown to be the start of a rise above the
99th centile.
Standard care was provided according to the existing guide-
lines at each hospital. These are outlined in table 2. Patients were
referred to the cardiology team if biomarkers were positive and
discharged (with or without exercise treadmill testing or referral
to an outpatient clinic) if negative. No attempt was made to
influence standard care at any hospital.
Patient management in both arms of the trial was at the
discretion of the physician and followed normal hospital
procedures, with the exception of use of the point-of-care panel
assessment in the intervention arm. All patients were followed
up by case note review and self-complete postal questionnaire at
1 and 3 months.
The primary outcome was the proportion of patients
successfully discharged home after emergency department
assessment. To be considered successfully discharged the patient
had to 1. have either left the hospital or be awaiting transport
home with a discharge decision having been made at 4 h after
initial presentation and 2. suffer no major adverse event (as
defined below) during the following 3 months. Secondary
outcomes included health utility (measured using the EQ-5D
self-complete questionnaire at 1 and 3 months after attendance),
length of initial hospital stay and total inpatient days over
3 months, use of coronary care, intensive care and cardiac
interventions and major adverse events (death, non-fatal acute
myocardial infarction, life-threatening arrhythmia, emergency
revascularisation or hospitalisation for myocardial ischaemia).
Diagnosis of myocardial infarction was based on the decision of
the most senior clinician recorded in the case notes. Emergency
revascularisation was defined as revascularisation performed
within 24 h of the decision to revascularise.
Case note review was used to identify hospital resource use
(length and location of hospital stay, use of cardiac interven-
tions, outpatient reviews, emergency department attendances
and subsequent hospital admissions), whereas the postal ques-
tionnaire was used to identify community and social care
resource use. Resources were valued using national unit costs4 5
to estimate total health and social care costs up to 3 months
after initial attendance.
The proportion of patients successfully discharged was
analysed through logistic regression, fitting concurrently with
intervention group the effect of centre and appropriate baseline
measures (including age, gender and past history of coronary
heart disease), to present adjusted odds ratios along with their
corresponding 95% CIs. The test for heterogeneity between
centres was tested by fitting an interaction between outcome
and centre, applying a likelihood ratio test. Cost analysis
compared bootstrap estimates of the mean cost per patient of
the two groups. It was anticipated that some of the resource use
data would be incomplete (missing). Thus, in order to maximise
the information collected from the trial, missing values were
imputed using multiple imputation.6 All analyses were under-
taken using the Stata statistical package (Release 10).
Table 1 Characteristics of the participating centres
Annual ED attendances.
1 April 2008 to 31 March 2009
Number of acute
medical beds* ED facilities On-site cardiology services
Barnsley 71 678 462 e CCU, rapid access clinic
Derriford 85 341 397 CDU CCU, angioplasty, cardiac surgery, rapid access clinic
Edinburgh 105 378 843y e CCU, angioplasty, cardiac surgery, rapid access clinic
Frenchay 62 823 461 CDU CCU, angioplasty, rapid access clinic
Leeds 109 362 491 CDU CCU, angioplasty, cardiac surgery, rapid access clinic
Leicester 156 053 290 e CCU, rapid access clinic
*Excluding escalation beds.
yBreakdown for medical beds not available, so all acute beds reported.
CDU, Clinical Decision Unit; CCU, Coronary Care Unit; ED, Emergency Department.
Table 2 Existing management strategies for low-risk chest pain
Location Troponin assay
Troponin
threshold
used(mg/l)
Troponin
99th
centile Laboratory analyser
Timing of
troponin (h)*
Other
biomarkers
Barnsley Inpatient ward Siemens Centaur Troponin I Ultra <0.2 0.04 Siemens Centaur XP 12
Derriford Clinical Decision Unit Roche Troponin T <0.01 <0.01 Roche Modular E170
(4th generation assay)
6
Edinburgh Medical Assessment Unit Abbott STAT Troponin I <0.05y 0.08 Architect i2000SR 12 Creatine kinase
Frenchay Clinical Decision Unit Beckman Coulter Access Accu Troponin I <0.06 0.04 Beckman Coulter Access 2 12
Leeds Clinical Decision Unit Siemens Centaur Troponin I Ultra <0.05 0.04 Siemens Centaur XP 12
Leicester Inpatient ward Siemens Centaur Troponin I Ultra <0.06 0.04 Siemens Centaur XP 12 Creatine kinase
*Timing after onset of worst symptoms.
yChanged from <0.2 on 21 January 2009. CHD, coronary heart disease.
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RESULTS
Patients were recruited between 30 January 2008 and 2 June
2009. Table 3 summarises the process of screening and recruit-
ment at each centre. All hospitals stopped recruitment on 2 June
2009 but the staggered start meant that some recruited for more
days than others. Overall, 2263 patients were recruited over
a total of 2658 hospital-days (0.9 patients per day). The total at
each site ranged from 327 to 469, and the recruitment rate
ranged from 0.7 to 1.1 per day.
Some 20 patients (seven in the point-of-care arm and 13 in the
standard care arm) did not complete initial follow-up to
recording of the primary outcome, so 2243 cases were available
for analysis. Mean age was 54.5 years, 1307/2243 (58%) were
male and 269 (12%) had known coronary heart disease. The
median time from worst symptoms to presentation was
129 min (IQR 80e246). The flow of patients through the trial is
shown in supplementary figure 1. Table 3 also shows the basic
characteristics of the participants at each centre.
Table 4 shows the proportion of patients successfully
discharged across all centres and at each centre. Point-of-care
panel assessment was associated with substantial increases in
successful discharge rates at Barnsley and Edinburgh, modest
increases at Derriford and Frenchay, and no increase at Leeds or
Leicester. The heterogeneity in outcomes was highly statistically
significant (c2¼75.5, degrees of freedom¼5, p<0.001), indicating
that the effect of point-of-care testing varied significantly
between the participating hospitals.
Figure 1 shows the proportion of patients in hospital as
a function of time from arrival. Point-of-care panel assessment
was associated with markedly fewer patients being in hospital
up to 24 h at Barnsley and Edinburgh. At Derriford the differ-
ence in proportion in hospital was only apparent between 4 and
8 h. At Frenchay the difference was marked up to 12 h, but after
12 h the proportion of patients in hospital was greater in the
point-of-care group. At Leeds the difference between the groups
did not emerge until 6 h after attendance, but between 6 and
24 h point-of-care panel assessment was associated with mark-
edly fewer patients being in hospital. Finally, at Leicester there
was no difference in the proportions in hospital up to 12 h and
only slightly fewer patients in hospital in the point-of-care
group from 12 to 36 h.
Table 5 shows the mean costs per patient in the two treat-
ment groups, across all centres and at each individual centre.
The difference between the mean costs at each centre are
reported with a 95% CI. This difference ranged from £214.49 less
in the point-of-care group at Leeds to £646.57 more at Edin-
burgh, but only the difference at Edinburgh was statistically
significant (p¼0.025). An ANOVA test across centres (based on
permuted test summed across the imputed data sets) yielded a p
value of 0.0803, indicating weak evidence of heterogeneity
between centres. The statistical power of this test to detect
variation between centres is limited by the large variances in
cost data, but it suggests that the effect of point-of-care panel
assessment on means costs per patient varied between hospitals.
DISCUSSION
The RATPAC trial showed that cardiac marker point-of-care
panel assessment increased the proportion of patients success-
fully discharged after emergency department assessment, but
the effect on the proportion of patients in hospital was limited
to the first 24 h after attendance.1 So, although median length of
stay was reduced, mean length of stay was unchanged. Costs
associated with point-of-care testing, additional coronary care
admissions and cardiac interventions meant that point-of-care
panel assessment did not save costs and may have increased
costs.2
This study has shown that the effect of point-of-care panel
assessment varied markedly between hospitals, suggesting that
the effect of point-of-care panel assessment may depend on the
setting and that the general findings of the RATPAC trial may
not apply at all hospitals. It is likely that differences in the
facilities available, local protocols, existing guidelines for chest
Table 3 Screening and recruitment
All centres Barnsley Derriford Edinburgh Frenchay Leeds Leicester
Recruitment:
Number of days recruiting 2658 490 464 427 429 413 435
Number of patients recruited 2263 327 328 457 469 353 329
Number of patients recruited /day 0.9 0.7 0.7 1.1 1.1 0.9 0.8
Number of patients analysed 2243 326 328 452 464 344 329
Mean (SD) age (years) 54.5 (14.1) 51.8 (14.4) 57.0 (13.9) 54.8 (13.6) 55.9 (14.4) 53.5 (13.5) 53.7 (14.4)
N (%) male 1307 (58.3) 185 (56.7) 204 (62.2) 252 (55.8) 271 (58.4) 200 (58.1) 195 (59.3)
N (%) with known coronary heart
disease
269 (12.0) 32 (9.8) 42 (12.8) 58 (12.8) 70 (15.1) 25 (7.3) 42 (12.8)
Median (SD) time from onset of worst
symptoms to arrival at hospital (min)
129 (80e246) 127 (69e308) 144 (93e261) 122 (79e224) 108 (75e187) 127 (73e238) 164 (100e314)
Table 4 Proportion of patients successfully discharged by study centre
Point of care Standard care OR* (95% CI) RDy (95% CI) p Value
Overall 358/1125 (32%) 146/1118 (13%) 3.81 (3.01 to 4.82) 18.7 (15.4 to 22.1) <0.001
Barnsley 110/162 (68%) 43/164 (26%) 6.97 (4.18 to 11.63) 41.3 (31.4 to 51.1) <0.001
Derriford 43/164 (26%) 21/164 (13%) 2.48 (1.37 to 4.49) 13.4 (5.0 to 21.9) 0.003
Edinburgh 104/228 (46%) 16/224 (7%) 11.07 (6.23 to 19.66) 38.4 (31.1 to 45.6) <0.001
Frenchay 50/233 (21%) 9/231 (4%) 7.03 (3.35 to 14.75) 17.4 (11.6 to 23.2) <0.001
Leeds 1/173 (1%) 8/171 (5%) 0.12 (0.01 to 1.03) 4.0 (7.2 to 0.7) 0.054
Leicester 50/165 (30%) 49/164 (30%) 1.11 (0.66 to 1.84) 0.4 (9.5 to 10.3) 0.699
*Adjusted for age, gender and known CHD. Overall result is also adjusted for centre. p Value corresponds to adjusted OR.
yRD, Absolute risk difference.
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pain, existing troponin assays or staff using the point-of-care
tests explain the variation in outcomes and costs. However,
caution should be taken about attempting to identify explana-
tions for outlying results in specific characteristics of the
hospital concerned. The estimates of proportion of patients
successfully discharged or mean costs per patient are subject to
substantial random error when analysed at individual hospital
level. For example, the reversed trend observed in the proportion
successfully discharged at Leeds was based on eight cases in the
control group versus one in the intervention group being
successfully discharged within 4 h after assessment. Further-
more, a statistically significant result for a specific hospital (such
as the comparison of mean costs per patient at Edinburgh) is one
of many hypothesis tests and thus carries a risk of being
a spurious false-positive finding.
Nevertheless, some evidence of the effect of local practice on
outcome seems to be apparent in figure 1, which shows the
differences between the hospitals in terms of the proportion of
patients in hospital as a function of time from initial attendance.
For example, standard care at Derriford was based on a troponin
level measured 6 h after arrival in hospital, which may explain
why the effect of point-of-care panel assessment at Derriford
was limited to the 4e8 h window. By contrast, at Leeds all
patients with chest pain are admitted to a Clinical Decision Unit
where diagnosis and management is undertaken without the
pressure of the 4 h target. This may explain why the effect of
point-of-care panel assessment was delayed at Leeds until 6 h
after arrival. Finally, at Leicester the point-of-care tests did not
seem to alter decision-making with regards to hospital admis-
sion. This may be because the point-of-care tests were
performed by research nurses at Leicester, leading to less ‘buy-in’
by the decision-making medical staff, whereas at other hospitals
they were performed by the physician. A number of other
factors may have influenced outcomes at different hospitals,
such as differences in the sensitivity or threshold used for the
troponin assay. Overall, the present analysis suggests that the
intervention would be more likely to have an impact at hospitals
where it is more distinct from standard care, where it helps to
address specific service targets and where it is used by decision-
making clinicians. However, these observations are difficult to
generalise between settings.
RATPAC is the only randomised trial to date to have exam-
ined the effect of point-of-care testing in a rapid rule-out
protocol. However, other trials3 7 have compared the use of
point-of-care and laboratory troponin assays. The DISPO-ACS
trial3 was a multicentre trial that evaluated point-of-care
troponin testing in four emergency departments and found that
the effect varied between settings, with length of stay in the
emergency department being increased in one hospital and
decreased in another. Meanwhile, the ESCAPE multicentre trial
of chest pain units showed that variation in the structure,
processes and outcomes of chest pain units was associated with
variation in unit activity, which was in turn associated with
differences in outcome between centres.8 9
Figure 1 Duration from arrival to
discharge from hospital (individual
centres). Solid line, point-of-care group;
dashed line, standard care group.
Table 5 Mean total costs per patient (£) by treatment group and site
Site
Point of care Standard care Difference
N Mean N Mean (95% CI) p Value
Barnsley 162 1058.33 164 923.13 135.20 (306.97 to 598.44) 0.538
Derriford 164 1466.81 164 1307.95 158.86 (326.84 to 679.23) 0.529
Edinburgh 228 1356.35 224 709.78 646.57 (73.12 to 1612.71) 0.025
Frenchay 233 1162.53 231 1058.33 104.20 (288.11 to 511.34) 0.625
Leeds 173 785.00 171 999.49 214.49 (657.10 to 132.56) 0.345
Leicester 165 1495.54 164 1115.41 380.13 (181.53 to 914.82) 0.148
Total 1125 1217.14 1118 1005.91 211.23 (16.53 to 442.90) 0.056
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These findings from multicentre trials suggest that there is
a pattern in the evaluation of chest pain diagnostic testing
regimes, whereby promising findings from earlier single-centre
studies are variably reproduced across multiple centres with only
a modest, negative or no overall effect. The implications of this
observation for interpreting research findings are twofold. First,
new diagnostic testing regimes should not be introduced on the
basis of positive experience at a single centre, which may be
atypical, but should be evaluated in multicentre trials before
widespread adoption. Second, negative findings from a multi-
centre trial, although suggesting that widespread adoption of
a testing regime is inappropriate, should not be considered proof
that the intervention cannot be effective in specific circum-
stances. It may be relatively easy within a single centre for the
medical staff to engage with a new intervention, whereas in
a multicentre trial physicians may be less willing to change their
behaviour. Future studies will need to collect more data about
system and physician factors that might influence the outcome
in order to better define the circumstance in which the inter-
vention may be of value.
The limitations of the main RATPAC analysis have previously
been outlined.1 The most relevant of these to this analysis is
that clinician behaviour (especially discharge decisions) may
have been influenced by participation in the trial. If this influ-
ence varied between hospitals then it could have produced some
of the variation observed in the results. Additional limitations
that relate to this particular study include 1. the trial was
powered on the basis of recruitment across all centres rather
than at each individual centre so it was underpowered to detect
potentially important differences at each centre, 2. analysis at
six different hospitals involves multiple hypothesis testing with
the associated risk of spurious false-positive findings and 3. the
six sites, although selected to represent a diverse range of
hospitals, were also selected on the basis of ability and willing-
ness to support research, so they may not be typical hospitals.
In conclusion, the effect of point-of-care panel assessment on
the proportion of patients successfully discharged and mean
costs per patient in the RATPAC trial varied between partici-
pating hospitals. This suggests that the impact of point-of-care
panel assessment depends on the setting in which it is used.
New diagnostic technologies should not be implemented until
they have been evaluated in diverse settings, and ideally in
multicentre studies that explore the interaction between the
setting and the effect of the intervention.
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